{"id":62203,"date":"2025-11-14T04:05:14","date_gmt":"2025-11-14T03:05:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/"},"modified":"2025-11-14T04:05:14","modified_gmt":"2025-11-14T03:05:14","slug":"tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/","title":{"rendered":"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery"},"content":{"rendered":"
\n

NEW YORK & BOSTON–(BUSINESS WIRE)–TandemAI announced it has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. The round included both new and existing investors. Since its founding in October 2021, the company has raised over $80M.<\/p>\n

<\/a>
<\/a><\/p>\n

\nWith a team of more than 300 professionals, TandemAI\u2019s AI-powered, fully integrated drug discovery engine has delivered over ten high-value, highly differentiated candidates that are now in\u2014or soon to enter\u2014clinical development. The company has also partnered with four of the world\u2019s top ten multinational pharmaceutical companies, building a network of more than 150 global partners and clients.<\/p>\n

\n\u201cTandemAI has successfully executed on its approach to build and commercialize a powerful drug discovery platform by integrating AI and physics-based computational technologies with wet lab techniques,\u201d said Peter Zhao, Managing Director at V-Capital. \u201cWith this funding, the company and its outstanding team are well positioned to grow its existing small molecule business and, with the recent merger with Perpetual Medicines, capitalize on the significant emerging opportunities in peptide and antibody-peptide conjugate discovery.\u201d<\/p>\n

\nKHK Fund stated, \u201cAI and advanced physics-based methods are now essential for drug discovery. TandemAI\u2019s platform has notably enhanced R&D efficiency and success rates in small molecule and peptide drug discovery, driving rapid growth even during the pharmaceutical market downturn. We are pleased to support the company\u2019s continued growth.\u201d<\/p>\n

\n\u201cThe financing is a strong vote of confidence in our progress to date and in our strategy,\u201d said Jeff He, co-founder and CEO of TandemAI. \u201cThis funding will support AI and computational physics-based model development for multiple modalities, as well as wet lab capacity expansion to accommodate our rapidly growing client base.\u201d Mr. He noted that the strategic merger with Perpetual Medicines also brought on board seasoned drug developers Kerry Blanchard, MD, PhD and Ved Srivastava, PhD, further enhancing TandemAI\u2019s end-to-end drug discovery and development expertise.<\/p>\n

\nAbout TandemAI<\/b><\/p>\n

\nTandemAI is transforming drug discovery by integrating generative AI, physics-based modeling (molecular dynamics and quantum mechanics), an AI-powered, next generation SaaS platform, TandemViz\u2122, and large-scale chemistry and biology labs. This computation-first approach covers the entire drug development process, from target prediction to clinical candidate determination, significantly boosting efficiency and success rates for global pharmaceutical organizations.<\/p>\n

\nIn just four years, TandemAI has established a global R&D, serving over 150 biopharmaceutical companies and accelerating more than 50 innovative drug pipelines. The company has achieved 10x revenue growth, earning accolades like “China Innovative Digital Healthcare TOP100,” “Forbes Asia 100 to Watch,” and inclusion in the “Nature Index Global AI Drug Discovery Innovation Landscape”.<\/p>\n

\nTandemViz\u2122, the world’s first one-stop AI-enabled drug discovery platform, integrates cutting edge computational modules, an optimized high-performance computing infrastructure, and data management, enhancing productivity and accessibility. This platform addresses key R&D challenges, driving rapid dry-wet lab integration and gaining widespread industry recognition. For additional information, please visit https:\/\/tandemai.com\/<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nJeff He, MBA
\n
CEO
\n
j.he@tandemai.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK & BOSTON–(BUSINESS WIRE)–TandemAI announced it has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. The round included both new and existing investors. Since its founding in October 2021, the company has raised over $80M. With a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62203","6":"format-standard","7":"category-industry"},"yoast_head":"\nTandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK & BOSTON–(BUSINESS WIRE)–TandemAI announced it has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. The round included both new and existing investors. Since its founding in October 2021, the company has raised over $80M. With a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T03:05:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251113520060\/en\/2643816\/22\/TANDEMAI_LOGO_USE_THIS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery\",\"datePublished\":\"2025-11-14T03:05:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/\"},\"wordCount\":510,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251113520060\\\/en\\\/2643816\\\/22\\\/TANDEMAI_LOGO_USE_THIS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/\",\"name\":\"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251113520060\\\/en\\\/2643816\\\/22\\\/TANDEMAI_LOGO_USE_THIS.jpg\",\"datePublished\":\"2025-11-14T03:05:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251113520060\\\/en\\\/2643816\\\/22\\\/TANDEMAI_LOGO_USE_THIS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251113520060\\\/en\\\/2643816\\\/22\\\/TANDEMAI_LOGO_USE_THIS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/","og_locale":"en_US","og_type":"article","og_title":"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery - Pharma Trend","og_description":"NEW YORK & BOSTON–(BUSINESS WIRE)–TandemAI announced it has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. The round included both new and existing investors. Since its founding in October 2021, the company has raised over $80M. With a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-14T03:05:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251113520060\/en\/2643816\/22\/TANDEMAI_LOGO_USE_THIS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery","datePublished":"2025-11-14T03:05:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/"},"wordCount":510,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251113520060\/en\/2643816\/22\/TANDEMAI_LOGO_USE_THIS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/","url":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/","name":"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251113520060\/en\/2643816\/22\/TANDEMAI_LOGO_USE_THIS.jpg","datePublished":"2025-11-14T03:05:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251113520060\/en\/2643816\/22\/TANDEMAI_LOGO_USE_THIS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251113520060\/en\/2643816\/22\/TANDEMAI_LOGO_USE_THIS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tandemai-closes-22m-series-a-extension-round-to-accelerate-ai-driven-drug-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TandemAI Closes $22M Series A Extension Round to Accelerate AI-Driven Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62203"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62203\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}